---
canonical_name: Muira Puama
alternate_names: Ptychopetalum olacoides, Muirapuama, Marapuama, Potency Wood
canonical_topic: Muira Puama for Health & Longevity
short_topic_lc: muira_puama
creation_date: 2026-1013-1924
creator_ai_fullname: Muse 1.0
---

# Muira Puama for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 10/13/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Muse 1.0

**Also known as:** Ptychopetalum olacoides, Muirapuama, Marapuama, Potency Wood

  
## Motivation

<!-- This section was written only after the rest of the document was written, to reflect the full scope of the topic. -->

Muira puama is a preparation from the root and bark of a small Amazonian tree, sold as an oral botanical supplement and as an ingredient in multi-ingredient formulas. It draws interest from health- and longevity-oriented adults mainly for questions around sexual vitality, mental sharpness, and everyday energy and mood. Those topics matter for quality of life across later decades, which places the plant within a broader discussion about maintaining function with age rather than treating a single diagnosed condition.

In parts of Brazil the plant has a long place in local traditional practice, where root preparations have been used as a general tonic and in connection with aging-related concerns. That history later brought laboratory and animal work on memory, mood, stress responses, and blood-vessel and nerve signaling, alongside a small number of human studies of combination products that included this plant among several ingredients.

This review examines what is known and what remains unknown about muira puama for health and longevity. It presents the evidence for and against proposed benefits, the reported harms and the limits of safety knowledge, how products are commonly formulated and used, and which open questions current research is positioned to address.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

This section lists directly relevant high-level overviews and qualifying papers on muira puama and closely related herbal approaches.

<!-- Search statement: On 10/13/2026 a real-time web search was performed for muira puama overviews, including "expert name + muira puama" searches and site searches for Rhonda Patrick (foundmyfitness.com), Peter Attia (peterattiamd.com), Andrew Huberman (hubermanlab.com), Chris Kresser (chriskresser.com), Life Extension Magazine (lifeextension.com), and Lifespan.io; a Life Extension Magazine testosterone article containing a dedicated muira puama section on Waynberg studies was found and assessed, but it is a testosterone overview rather than a high-level overview of muira puama itself, so it was not listed, and no directly relevant content from the other priority experts was found. Qualifying narrative reviews and primary papers below were verified via PubMed. -->

- [A review of plant-derived and herbal approaches to the treatment of sexual dysfunctions](https://pubmed.ncbi.nlm.nih.gov/12851124/) - Rowland & Tai, 2003

  Narrative review cataloguing herbal agents sold for sexual problems, with dose, adverse effects, and evidence quality for each. Useful context for placing muira puama among comparable botanicals.

- [Ethnobotanical treatment strategies against Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/22329652/) - Howes & Houghton, 2012

  Narrative review of plants traditionally used for memory disorders, including this species. It separates plants with human data from those supported only by laboratory findings.

- [Pharmacology of Herbal Sexual Enhancers: A Review of Psychiatric and Neurological Adverse Effects](https://pubmed.ncbi.nlm.nih.gov/33066617/) - Brunetti et al., 2020

  Narrative safety review covering this species among herbal sexual enhancers. It emphasizes unstandardized products, combined use, and the scarcity of controlled human safety data.

- [Selected herbals and human exercise performance](https://pubmed.ncbi.nlm.nih.gov/10919969/) - Bucci, 2000

  Narrative review of herbs promoted for physical performance, including muira puama. It distinguishes tested from virtually untested herbs and sets out standards for credible human trials.

A Life Extension Magazine testosterone overview containing a muira puama section was found but is not listed, because it is not a high-level overview of muira puama itself; no other priority-expert content was found, and fewer than five high-quality qualifying sources exist, so the list is not padded with marginally relevant content.

  
## Grokipedia

<!-- Search statement: grokipedia.com was searched directly on 10/13/2026 using d-browser (browser_navigate to grokipedia.com/search?q=muira+puama, then browser_snapshot); d-browser returned 5 results including a dedicated Ptychopetalum page, which loaded successfully. No further retrieval tiers were needed. -->

[Ptychopetalum](https://grokipedia.com/page/Ptychopetalum)

Dedicated page on the genus that supplies muira puama, covering traditional use, commercial harvesting, and supplement status. It provides background context rather than clinical evidence.

  
## Examine

<!-- Search statement: examine.com was searched directly on 10/13/2026. d-browser returned a Vercel Security Checkpoint bot wall; d-fetch returned status 429; d-proxy-2 (scrape_as_markdown) returned the genuine search results and the dedicated supplement page titled "Muira puama", last updated August 28, 2025. -->

[Muira puama](https://examine.com/supplements/muira-puama/)

Dedicated supplement page summarizing traditional use and the lack of quality human trials, with dosage information for concentrated extracts. It is the most accessible evidence-oriented overview available.

  
## ConsumerLab

<!-- Search statement: consumerlab.com was searched directly on 10/13/2026 using d-browser (browser_navigate to consumerlab.com/search/?search=muira+puama, then browser_snapshot); d-browser returned the genuine search page with no matching article or product review listed. No further tiers were needed. -->

No ConsumerLab article on muira puama was found.

  
## Systematic Reviews

No systematic reviews or meta-analyses for Muira Puama were found on PubMed as of 10/13/2026.

  
## Mechanism of Action

Muira puama root and bark extracts contain many plant compounds, and no single active ingredient or human blood level has been established. Laboratory work points to several partly separate actions rather than one proven pathway. In rat brain tissue and in aged mice, an ethanol extract (an alcohol-based preparation) slowed acetylcholinesterase (an enzyme that breaks down acetylcholine, a messenger involved in memory), which is proposed as one link to the memory findings in animals [Siqueira et al.](https://pubmed.ncbi.nlm.nih.gov/12895682/). Mouse studies of mood-like behavior implicate dopamine (a messenger involved in motivation) and beta-adrenergic receptors (receptors that respond to adrenaline-like signals), because blocking those receptors prevented the effect, while blocking serotonin (a messenger involved in mood) production did not [Piato et al.](https://pubmed.ncbi.nlm.nih.gov/19067380/). A second line of work concerns nitric oxide (a signaling gas that relaxes blood vessels): in cultured rat penile smooth-muscle cells, a four-ingredient combination containing muira puama, studied by the group that developed it, raised inducible nitric oxide synthase (an enzyme that makes nitric oxide when switched on) and cyclic guanosine monophosphate (a messenger that relaxes smooth muscle), while muira puama alone was weaker than the combination [Ferrini et al.](https://pubmed.ncbi.nlm.nih.gov/29551532/). Because the extract is a mixture, human half-life (time for blood levels to fall by half), tissue distribution, selectivity, and metabolic enzymes are unknown; no human pharmacokinetic (how the body absorbs and clears a substance) study was found.

  
## Historical Context & Evolution

Communities in the Brazilian Amazon have long prepared alcohol infusions and decoctions (hot-water extracts) from the roots of *Ptychopetalum olacoides* (the botanical name for muira puama). Published ethnopharmacology (the study of traditional plant medicines) papers describe those preparations as a nerve tonic used for lack of motivation and weariness, for sexual concerns, and for complaints associated with aging, including memory [da Silva et al.](https://pubmed.ncbi.nlm.nih.gov/15507336/). During the twentieth century the dried root and bark entered commercial herbal trade in Brazil and abroad, often blended with other Amazonian plants in tonic formulas. Scientific interest followed the traditional claims rather than preceding them: from the early 2000s, a Brazilian research group tested a standardized ethanol extract in mice for memory retrieval, mood-like and stress behavior, and anxiety-like behavior, reporting effects in some tests and an anxiety-like signal in another. In parallel, researchers interested in erectile function (ability to achieve an erection) included muira puama in a four-ingredient combination studied in aging rats and later in small human pilot work. Scientific opinion has therefore not moved from rejection to acceptance; it has accumulated preclinical (animal and laboratory) findings and small uncontrolled human observations without the controlled trials that would settle whether traditional impressions reflect a specific effect of this plant.

  
## Expected Benefits

<!-- Search statement: On 10/13/2026 a dedicated PubMed search for "muira puama" OR Ptychopetalum olacoides (50 records) plus clinical and expert sources was performed for the complete benefit profile, including searches for studies of any design finding no effect or the opposite effect; no controlled human trial of muira puama alone and no null randomized trial was found. -->

### High 🟩 🟩 🟩

No benefit reaches High: the human data are small uncontrolled studies of multi-ingredient combinations, and the single-plant data are animal and in-vitro (laboratory dish) studies.

### Medium 🟩 🟩

No benefit reaches Medium: there is no controlled human trial, from any research group, testing muira puama alone or in combination against a comparison group.

### Low 🟩

#### Sexual desire and satisfaction in women

In an uncontrolled 1-month study, 202 women reporting low sex drive rated desire and satisfaction higher after a muira puama–*Ginkgo biloba* combination [Waynberg & Brewer](https://pubmed.ncbi.nlm.nih.gov/11186145/). The evidence is indirect: muira puama was tested only with another treatment, without a comparison group.

**Magnitude:** 65% of participants had higher average total self-assessment scores after 1 month (no control group).

#### Erectile function in men

In an uncontrolled 3-month pilot, 54 men with erectile dysfunction (difficulty achieving an erection) took a muira puama combination; scores rose among those remaining [Nguyen et al.](https://pubmed.ncbi.nlm.nih.gov/29732286/). The evidence is indirect: muira puama was tested only with other treatments.

**Magnitude:** Median erectile-function domain score was 21 at 1 month versus 16 at baseline among those remaining on the regimen (no control group).

### Speculative 🟨

#### Memory retrieval

Single extract doses improved memory retrieval in young and aging mice [da Silva et al.](https://pubmed.ncbi.nlm.nih.gov/15507336/). No human cognition (thinking and memory) data exist; the basis is animal work only.

#### Mood and stress resilience

Extract showed antidepressant-like effects in mice, linked to dopamine and adrenaline-like signaling [Piato et al.](https://pubmed.ncbi.nlm.nih.gov/19067380/), and prevented chronic-stress changes [Piato et al.](https://pubmed.ncbi.nlm.nih.gov/19682881/). No human mood data exist; basis is animal work only.

#### Blood-vessel nitric oxide signaling

A muira puama combination increased nitric oxide signaling in cultured human vessel cells [Ferrini et al.](https://pubmed.ncbi.nlm.nih.gov/39913351/). No human outcome data exist; the basis is cell and animal work.

  
## Benefit-Modifying Factors

- **Genetic polymorphisms (inherited gene variants):** No gene variant has been studied for muira puama response in humans; no pharmacogenetic (gene-based drug response) data exist.
- **Baseline biomarker levels (measurable body signals):** No baseline blood marker has been shown to predict benefit; human studies enrolled participants by symptoms, not biomarkers.
- **Sex-based differences:** Human combination data exist separately in women reporting low desire and in men with erectile dysfunction; no study compares response by sex.
- **Pre-existing health conditions:** Benefit reports come from people with sexual complaints; effects in people without such complaints, or with cardiovascular (heart and blood vessel) disease, are unstudied.
- **Age:** Aging mice responded in memory tests and human pilot participants were mostly middle-aged; benefit at older ages in humans is untested.

  
## Potential Risks & Side Effects

<!-- Search statement: On 10/13/2026 a dedicated search for the complete side effect profile was performed using PubMed adverse-effect and toxicity queries and drug reference sources (Drugs.com and WebMD muira puama monographs, which report limited side-effect research and no pregnancy safety data), including searches for studies finding no excess risk; the 28-day Catuama toxicology study and the Revactin pilot safety data below were identified. -->

### High 🟥 🟥 🟥

No risk reaches High: there are no replicated controlled human adverse-event (harmful or unwanted effect) data from independent research groups for muira puama.

### Medium 🟥 🟥

No risk reaches Medium: the human safety data are small uncontrolled combination studies, and single-plant harm signals come from animal work.

### Low 🟥

#### Digestive upset and headache during combination use

In a 54-man combination pilot, five reported dyspepsia (indigestion), heartburn, or migraine (severe headache), none severe [Nguyen et al.](https://pubmed.ncbi.nlm.nih.gov/29732286/). A 28-day combination study found no severe reactions [Oliveira et al.](https://pubmed.ncbi.nlm.nih.gov/15798997/). Both are indirect: other ingredients were included.

**Magnitude:** Side effects were reported by 5 of 54 men in the combination pilot study (no control group).

### Speculative 🟨

#### Anxiety-like stimulation

Extract reduced exploratory behavior in mice, matching an anxiety-provoking reference compound [da Silva et al.](https://pubmed.ncbi.nlm.nih.gov/12164265/). No human anxiety data exist; the basis is animal work only.

#### Blood-pressure and bleeding effects through nitric oxide signaling

Combinations raise nitric oxide signaling and lower a clotting-related marker in vessel cells, potentially relaxing vessels and reducing clot stability [Ferrini et al.](https://pubmed.ncbi.nlm.nih.gov/39913351/). No human blood-pressure or bleeding data exist; basis is mechanistic.

  
## Risk-Modifying Factors

- **Genetic polymorphisms:** No inherited variant affecting muira puama metabolism (body breakdown) or risk has been identified in humans.
- **Baseline biomarker levels:** No baseline blood marker is known to predict harm; combination studies monitored routine blood tests for 28 days only.
- **Sex-based differences:** No sex-specific risk pattern is established; human combination data include both sexes without comparative safety analysis.
- **Pre-existing health conditions:** Anxiety disorders, low blood pressure, and liver or kidney problems are unstudied contexts where stimulant-like or vessel effects could matter more.
- **Age:** Safety beyond middle age is largely untested; older adults commonly take more interacting medications, raising practical risk.

  
## Key Interactions & Contraindications

<!-- Search statement: On 10/13/2026 a dedicated PubMed search for muira puama with "drug interaction" OR pharmacokinetics was performed; no published human interaction or pharmacokinetic study of muira puama was found, so interactions below are inferred from mechanism and marked (theoretical) where applicable. -->

- **Phosphodiesterase-5 inhibitors (erectile-dysfunction medications such as sildenafil and tadalafil):** Caution (theoretical) — additive vessel relaxation could lower blood pressure; no human interaction study exists.
- **Nitrates and blood-pressure medications (nitroglycerin, amlodipine, losartan):** Caution (theoretical) — additive blood-pressure lowering is possible through nitric oxide signaling; blood-pressure monitoring is the stated mitigation in trial protocols.
- **Stimulants and activating antidepressants (methylphenidate, bupropion):** Caution (theoretical) — animal data suggest dopamine and adrenaline-like activity, so additive stimulation or anxiety is possible.
- **Cholinesterase inhibitors (memory medications such as donepezil):** Caution (theoretical) — laboratory acetylcholinesterase slowing could add to these medications, increasing nausea (feeling sick) or slowed heart rate; no human data exist.
- **Sedatives and sleep medications (zolpidem, benzodiazepines such as lorazepam):** Monitor (theoretical) — a stimulating tonic could oppose intended sedation (drowsiness), based on traditional positioning and animal behavior.
- **Over-the-counter medications (pseudoephedrine, caffeine, diphenhydramine):** Monitor (theoretical) — nasal decongestants (medications for a blocked nose) and caffeine could add to stimulant-like effects, while sedating sleep aids could be opposed; no human study exists.
- **Other sexual-enhancement supplements (yohimbe, L-citrulline (an amino acid), guarana):** Caution (theoretical) — products are often stacked, compounding stimulant and vessel effects and product-quality uncertainty.

**Populations who should avoid Muira Puama:**

- People who are pregnant or breastfeeding, because safety and efficacy data are lacking in drug reference monographs
- Children and adolescents, because no pediatric (child) safety data exist
- People with a known allergy to muira puama, an exclusion criterion in the registered combination trials [NCT05595915](https://clinicaltrials.gov/study/NCT05595915)

  
## Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

- **Start low, single ingredient first:** Beginning with a single-ingredient product at the lowest labeled dose limits digestive upset and makes adverse effects attributable.
- **Morning administration:** Oral use earlier in the day reduces the chance that stimulant-like effects disturb sleep or worsen anxiety-like stimulation.
- **Avoid stacking sexual-enhancement products:** Not combining with yohimbe, guarana, or similar products limits additive stimulation, headache, and blood-pressure effects.
- **Blood-pressure check when combined:** Measuring blood pressure before and during combined use with vessel-relaxing medications addresses theoretical additive lowering.
- **Stop for persistent symptoms:** Discontinuing when indigestion, heartburn, headache, agitation, or insomnia (difficulty sleeping) persists prevents continued exposure to an unstandardized product.
- **Time-limited trial:** Limiting initial use to the 1–3 month durations used in human combination studies avoids untested long-term exposure [Nguyen et al.](https://pubmed.ncbi.nlm.nih.gov/29732286/).

  
## Therapeutic Protocol

Other parameters without a citation (timing, cycling, titration steps) reflect common practice.

- **Concentrated extract dose:** Examine lists 1,000–1,500 mg daily of a 4:1 concentrated extract, equivalent to 4,000–6,000 mg basic extract [Muira puama](https://examine.com/supplements/muira-puama/).
- **Combination dose studied in men:** The Revactin pilot used a total daily 500 mg of ginger, muira puama, and guarana plus 1,600 mg L-citrulline, split twice daily [Nguyen et al.](https://pubmed.ncbi.nlm.nih.gov/29732286/).
- **Trial dose for vessel outcomes:** The registered COMP-4 trial used capsules with 125 mg muira puama each, two capsules twice daily for 14 days [NCT05595915](https://clinicaltrials.gov/study/NCT05595915).
- **Best time of day:** Morning or early afternoon oral administration is common practice for a tonic positioned as stimulating; evening use is avoided in practice.
- **Half-life:** Unknown in humans; no human pharmacokinetic study of the extract or its constituents was found, so accumulation cannot be estimated.
- **Single versus split doses:** Combination studies split the daily amount twice daily; no comparison of single versus split dosing exists for muira puama alone.
- **Genetic polymorphisms:** No inherited variant is known to influence dose choice; no genetic testing is part of any reported protocol.
- **Sex-based differences:** No sex-specific dosing is established; the women’s and men’s combination studies used different products and cannot be compared.
- **Age considerations:** Human data are mainly in middle-aged adults; no dose adjustment for older adults has been studied.
- **Baseline biomarkers:** No biomarker-guided dosing exists; enrollment in human studies was by symptoms and general health status.
- **Pre-existing conditions:** Cardiovascular disease, anxiety disorders, and liver or kidney problems were largely excluded or unstudied in human work.

  
## Discontinuation & Cycling

- **Duration of use:** Human combination exposures lasted 1–3 months; whether use is short-term or ongoing has not been studied beyond those periods.
- **Withdrawal effects:** No withdrawal syndrome (symptoms on stopping) has been reported in the human combination studies; dependence has not been formally studied.
- **Tapering:** No tapering-off (gradual dose reduction) protocol has been published; human studies stopped administration at study end.
- **Cycling:** No cycling schedule (planned on–off periods) has been tested for maintaining efficacy (effectiveness under study conditions) in humans.
- **Loss of effect:** Tolerance (reduced effect over time) has not been measured; the 3-month pilot tracked scores only among participants who continued.

  
## Sourcing and Quality

- **Botanical identity:** Products should name *Ptychopetalum olacoides* and the plant part (root or bark), because common names are applied inconsistently in trade.
- **Extraction ratio:** Labels stating extract strength, such as 4:1, allow comparison with the dosages summarized by Examine [Muira puama](https://examine.com/supplements/muira-puama/).
- **Third-party testing:** Independent testing for identity, heavy metals, microbes, and undeclared drugs matters especially in sexual-enhancement products, a category with adulteration (hidden added drugs) concerns.
- **Standardization limits:** No accepted marker compound defines potency; research extracts were laboratory-standardized ethanol extracts, not typical retail powders.
- **Reputable sourcing:** Established supplement brands publishing certificates of analysis (lab test reports) are preferable to unlabeled bulk powders or multi-ingredient blends with undisclosed amounts.
- **Sustainability:** Root and bark harvesting affects wild Amazonian trees; suppliers stating cultivated or managed harvest sources reduce ecological pressure.

  
## Practical Considerations

- **Time to effect:** Human combination studies assessed outcomes after 1 month in women and monthly over 3 months in men; onset for muira puama alone is unknown.
- **Common pitfalls:** Attributing combination-product results to muira puama alone, stacking stimulant blends, and assuming retail powders match research ethanol extracts.
- **Regulatory status:** In the United States, muira puama is sold as a dietary supplement, a category the Food and Drug Administration (the US food and drug regulator) oversees without premarket approval of efficacy [FDA 101: Dietary Supplements](https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements).
- **Cost and accessibility:** Single-ingredient capsules are inexpensive and widely sold online; cost is not a major barrier compared with product-quality uncertainty.
- **Form variability:** Teas, tinctures (alcohol extracts), powders, and concentrated extracts deliver different constituent profiles, complicating comparison across products and studies.

  
## Interaction with Foundational Habits

- **Sleep:** Indirect, potentially blunting — stimulant-like animal behavior and tonic positioning suggest evening use could disturb sleep, so morning administration is common practice.
- **Nutrition:** None established — no nutrient depletion or diet pairing is documented; alcohol-based traditional preparations add alcohol exposure independent of the plant.
- **Exercise:** Indirect — muira puama is among herbs promoted for performance but virtually untested for exercise outcomes in controlled human work [Bucci](https://pubmed.ncbi.nlm.nih.gov/10919969/).
- **Stress management:** Indirect and mixed — mouse work reports anti-stress effects under chronic stress [Piato et al.](https://pubmed.ncbi.nlm.nih.gov/19682881/) and an anxiety-like pattern in another test [da Silva et al.](https://pubmed.ncbi.nlm.nih.gov/12164265/), so direction in humans is unresolved.

  
## Monitoring Protocol & Defining Success

Baseline assessment before starting centers on the specific outcome prompting use, current medications and supplements with vessel or stimulant effects, pregnancy status where relevant, and resting blood pressure and pulse recorded under consistent conditions. Because no human study of muira puama alone defines a target blood marker, baseline laboratory testing is limited to safety context rather than expected change. Ongoing monitoring repeats blood pressure and pulse at 2 weeks, 1 month, and then every 1–3 months during continued use, alongside review of headache, digestive symptoms, agitation, and sleep disturbance. Success is defined against the individual’s own baseline symptom record over a 1–3 month period matching human combination-study durations, not against a population threshold.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Blood pressure | No established target — track change from the individual’s own baseline | Safety check | Seated, same time of day; relevant when combined with vessel-relaxing medications |
| Resting pulse | 60–100 beats per minute (standard reference range) | Safety check | Morning resting measurement; a sustained rise suggests stimulant-like effects |

- Sexual desire, satisfaction, and erectile function recorded with the same brief questionnaire at baseline and monthly
- Energy, motivation, and perceived mental sharpness rated weekly on a simple numeric scale
- Sleep quality, agitation, headache, and digestive symptoms logged weekly as tolerability markers

  
## Emerging Research

- **COMP-4 and brachial artery dilation:** Single-group Phase 1/2 trial in 32 young healthy adults testing 14 days of the muira puama combination on flow-mediated dilation (ultrasound measure of vessel relaxation); completed 2025, no results posted [NCT05595915](https://clinicaltrials.gov/study/NCT05595915). A positive result would support vessel effects; a null result would weaken that case.
- **COMP-4 and plasminogen activator inhibitor-1:** Open-label (participants know the treatment) 6-week trial in 35 healthy adults measuring a clotting-related aging marker; active, not recruiting [NCT07469475](https://clinicaltrials.gov/study/NCT07469475). A sustained decrease would strengthen vascular claims; no change would narrow them.
- **Endothelial cell protection:** Cell work reports the combination raises nitric oxide availability and lowers inflammatory signals in human vessel cells (eNOS and iNOS are enzymes that make nitric oxide; cGMP is a messenger that relaxes smooth muscle) [Nutraceutical COMP-4 confers protection against endothelial dysfunction through the eNOS/iNOS-NO-cGMP pathway](https://pubmed.ncbi.nlm.nih.gov/39913351/) - Ferrini et al., 2025.
- **Missing controlled human trials:** No registered trial tests muira puama alone for cognition, mood, or sexual function, leaving the oldest traditional claims without a decisive human test.

  
## Conclusion

Muira puama is an Amazonian root and bark preparation with a long traditional life as a tonic linked to sexual vitality, mental sharpness, energy, and mood. For health- and longevity-oriented adults, the human evidence remains thin: the only human outcome reports come from small studies without comparison groups, and in each case muira puama was combined with other active ingredients, so any share belonging to this plant alone cannot be separated. Animal and laboratory work offers a richer picture, spanning memory tests in mice, mood-related behavior, and blood-vessel signaling in cells and rats, yet none of that has been confirmed in controlled human studies. On safety, short combination exposures produced mostly mild digestive and headache complaints, while an anxiety-like signal in animals, possible interplay with vessel-relaxing and stimulating medicines, and the absence of pregnancy and long-term safety data leave important gaps. Product quality adds further uncertainty, since extracts vary, no agreed potency marker exists, and much of the supportive combination research comes from groups developing those very formulas. Overall, the evidence presents an intriguing traditional remedy whose proposed benefits for healthy aging remain unproven in people, with the mild side effects seen during short-term combination use the clearest human finding so far.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**







